Prepare for your exams
Get points
Guidelines and tips

Prepare for your exams

Study with the several resources on Docsity

Earn points to download

Earn points by helping other students or get them with a premium plan

Guidelines and tips

Sell on Docsity

Log in Sign up

Prepare for your exams

Study with the several resources on Docsity

Find documents

Prepare for your exams with the study notes shared by other students like you on Docsity

Search Store documents

The best documents sold by students who completed their studies

Search through all study resources

Docsity AINEW

Summarize your documents, ask them questions, convert them into quizzes and concept maps

Explore questions

Clear up your doubts by reading the answers to questions asked by your fellow students

Earn points to download

Earn points by helping other students or get them with a premium plan

Share documents

20 Points

For each uploaded document

Answer questions

5 Points

For each given answer (max 1 per day)

All the ways to get free points

Get points immediately

Choose a premium plan with all the points you need

Study Opportunities

Choose your next study program

Get in touch with the best universities in the world. Search through thousands of universities and official partners

Community

Ask the community

Ask the community for help and clear up your study doubts

University Rankings

Discover the best universities in your country according to Docsity users

Free resources

Our save-the-student-ebooks!

Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors

From our blog

Exams and Study

Go to the blog

Funding Status & Differences: Redesca vs. Lovenox® Biosimilars in Ontario, Canada, Study notes of Clinical Medicine

American College of Hairstyling Clinical Medicine

Information on the funding status and differences between redesca and lovenox®, two enoxaparin biosimilars approved by health canada. Redesca is a biosimilar version of lovenox® and is now funded through the ontario drug benefit (odb) formulary as a general benefit, while lovenox® remains unchanged at this time. The rationale behind the funding change and the impact on patients.

What you will learn

What is the difference between Redesca and Lovenox® enoxaparin biosimilars?
Why was the funding status of Redesca enoxaparin changed?
How does the funding change for Redesca enoxaparin impact patients?

Typology: Study notes

2021/2022

Uploaded on 09/12/2022

themask 🇺🇸

4.4

(17)

315 documents

1 / 3

This page cannot be seen from the preview

Don't miss anything!

Ministry of Health

Drugs and Devices Division

1

Enoxaparin Frequently Asked Questions

1. What is the difference between Redesca (HP) and Lovenox® (HP)?

Redesca and Lovenox® are both enoxaparin products. Enoxaparin belongs to

a class of chemicals called low molecular weight heparin (LMWH) and is used

for the treatment and prevention of blood clots. Redesca (enoxaparin) is

approved by Health Canada as a biosimilar version of the originator

enoxaparin biologic product known as Lovenox®. Redesca (enoxaparin) and

Lovenox® (enoxaparin) are manufactured and marketed by different

companies.

2. What is the funding status of Redesca (enoxaparin)?

Effective with the April 2021 Formulary update (April 30, 2021), Redesca

(enoxaparin) will be listed on the Ontario Drug Benefit (ODB)

Formulary/Comparative Drug Index (Formulary) as a General Benefit.

DIN

Brand

Name

Generic

Name

Strength &

Dosage Form

MFR

02509121

Redesca®

enoxaparin

100mg/mL Inj

Sol-3mLVial Pk

Valeo

Pharmac

Inc.

02509075

Redesca®

enoxaparin

30mg/0.3mL

Pref Syr-0.3mL

Pk

Valeo

Pharmac

Inc.

02509083

Redesca®

enoxaparin

40mg/0.4mL

Pref Syr-0.4mL

Pk

Valeo

Pharmac

Inc.

02509091

Redesca®

enoxaparin

60mg/0.6mL

Pref Syr-0.6mL

Pk

Valeo

Pharmac

Inc.

02509105

Redesca®

enoxaparin

80mg/0.8mL

Pref Syr-0.8mL

Pk

Valeo

Pharmac

Inc.

Partial preview of the text

Download Funding Status & Differences: Redesca vs. Lovenox® Biosimilars in Ontario, Canada and more Study notes Clinical Medicine in PDF only on Docsity!

Drugs and Devices Division Enoxaparin Frequently Asked Questions

1. What is the difference between Redesca (HP) and Lovenox® (HP)? Redesca and Lovenox ® are both enoxaparin products. Enoxaparin belongs to a class of chemicals called low molecular weight heparin (LMWH) and is used for the treatment and prevention of blood clots. Redesca (enoxaparin) is approved by Health Canada as a biosimilar version of the originator enoxaparin biologic product known as Lovenox®. Redesca (enoxaparin) and Lovenox® (enoxaparin) are manufactured and marketed by different companies. 2. What is the funding status of Redesca (enoxaparin)? Effective with the April 2021 Formulary update (April 30, 2021), Redesca (enoxaparin) will be listed on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index (Formulary) as a General Benefit. DIN Brand Name Generic Name Strength & Dosage Form

MFR

02509121 Redesca® enoxaparin 100mg/mL Inj Sol-3mLVial Pk Valeo Pharmac Inc. 02509075 Redesca® enoxaparin 30mg/0.3mL Pref Syr-0.3mL Pk Valeo Pharmac Inc. 02509083 Redesca® enoxaparin 40mg/0.4mL Pref Syr-0.4mL Pk Valeo Pharmac Inc. 02509091 Redesca® enoxaparin 60mg/0.6mL Pref Syr-0.6mL Pk Valeo Pharmac Inc. 02509105 Redesca® enoxaparin 80mg/0.8mL Pref Syr-0.8mL Pk Valeo Pharmac Inc.

Drugs and Devices Division DIN Brand Name Generic Name Strength & Dosage Form

MFR

Redesca HP® enoxaparin 120mg/0.8mL Pref Syr-0.8mL Pk Valeo Pharmac Inc. 02509113 Redesca® enoxaparin 100mg/mL Pref Syr-1mL Pk Valeo Pharmac Inc. 02509156 Redesca HP® enoxaparin 150mg/mL Pref Syr-1mL Pk Valeo Pharmac Inc.

3. What is the funding status of Lovenox (enoxaparin)? In view of implementation considerations and ongoing COVID-19 priorities in Ontario, the funding status of Lovenox products on the ODB Formulary and under the Exceptional Access Program (EAP) will remain unchanged at this time. Further changes to the funding status of Lovenox products will be announced at a later date. 4. What is the rationale behind changing the funding status for enoxaparin? Redesca (enoxaparin) was approved by Health Canada as a biosimilar version of enoxaparin. The originator version of enoxaparin is Lovenox®. Biosimilars are not identical to originator biologics. However, Health Canada conducts rigorous testing to ensure that biosimilars have a highly similar structure, are equally as safe, and have the same therapeutic effect as an originator biologic. Biosimilars also present an opportunity to achieve better value for money for biologic drugs that will help to support the long-term sustainability and accessibility of Ontario’s public drug programs. 5. How will these changes impact patients? As of the April 2021 Formulary Update, ODB eligible patients wishing to receive treatment with enoxaparin therapy may access Redesca funded through the ODB Formulary as a GB.